Idenix (IDIX) Shares at Intraday Low; INFORM-SVR Data Has Negative Implications & Abbott (ABT) Positive Hep C Studies
Get Alerts IDIX Hot Sheet
Price: $24.50 --0%
Rating Summary:
1 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Rating Summary:
1 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Shares of Idenix (Nasdaq: IDIX) are trading close to intraday lows, currently at $8.99, down $1.26 (-12.31%).
Brean Murray analyst, Brian Skorney, made comments after Roche's (OTC: RHHBY) reported unacceptable relapse rates for patients taking mericitabine+danoprevir+ritonavir+ribavirin for 12 wks.
Skorney, said, "We believe Idenix (Sell-rated) will need to explore regimens with durations of greater than 12 weeks to be effective. Given that the company has yet to initiate preclinical tox work in excess of 12 weeks, we believe this could significantly delay clinical development and makes IDX184 substantially less attractive as a potential backbone therapy."
Separately, shares of Idenix may be selling off after a report out from Abbott Labs (NYSE: ABT) this morning regarding results from clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV).
In the study known as "Co-Pilot," different doses of ABT-450/r, plus ABT-333 and ribavirin administered for 12 weeks showed sustained virological response at 12 weeks post treatment (SVR12) in 95% and 93% of treatment-naive genotype 1 (GT1) patients.
In a separate study, known as "Pilot," 91% of genotype 1 infected, treatment-naive patients taking ABT-450/r and ABT-072 combined with ribavirin administered for 12 weeks, achieved sustained viral response at 24 weeks (SVR24).
Brean Murray analyst, Brian Skorney, made comments after Roche's (OTC: RHHBY) reported unacceptable relapse rates for patients taking mericitabine+danoprevir+ritonavir+ribavirin for 12 wks.
Skorney, said, "We believe Idenix (Sell-rated) will need to explore regimens with durations of greater than 12 weeks to be effective. Given that the company has yet to initiate preclinical tox work in excess of 12 weeks, we believe this could significantly delay clinical development and makes IDX184 substantially less attractive as a potential backbone therapy."
Separately, shares of Idenix may be selling off after a report out from Abbott Labs (NYSE: ABT) this morning regarding results from clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV).
In the study known as "Co-Pilot," different doses of ABT-450/r, plus ABT-333 and ribavirin administered for 12 weeks showed sustained virological response at 12 weeks post treatment (SVR12) in 95% and 93% of treatment-naive genotype 1 (GT1) patients.
In a separate study, known as "Pilot," 91% of genotype 1 infected, treatment-naive patients taking ABT-450/r and ABT-072 combined with ribavirin administered for 12 weeks, achieved sustained viral response at 24 weeks (SVR24).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hyundai Motor (005380:KS) (HYMTF) PT Raised to KRW290 at Citi
- Cantor Fitzgerald Downgrades Caledonia Mining Corporation (CMCL) to Hold
- Cintas (CTAS) PT Raised to $725 at RBC Capital
Create E-mail Alert Related Categories
Analyst Comments, Trader TalkRelated Entities
Brean Murray Carret & Co.Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!